GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (NAS:NOTV) » Definitions » Interest Coverage

Inotiv (Inotiv) Interest Coverage : 0 (At Loss) (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Inotiv Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Inotiv's Operating Income for the three months ended in Dec. 2023 was $-8.3 Mil. Inotiv's Interest Expense for the three months ended in Dec. 2023 was $-11.4 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Inotiv's Interest Coverage or its related term are showing as below:

NOTV' s Interest Coverage Range Over the Past 10 Years
Min: 0.05   Med: 1.06   Max: 3.41
Current: 0.12


NOTV's Interest Coverage is ranked worse than
100% of 102 companies
in the Medical Diagnostics & Research industry
Industry Median: 9.17 vs NOTV: 0.12

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Inotiv Interest Coverage Historical Data

The historical data trend for Inotiv's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Inotiv Interest Coverage Chart

Inotiv Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.68 -

Inotiv Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.94 0.34 -

Competitive Comparison of Inotiv's Interest Coverage

For the Diagnostics & Research subindustry, Inotiv's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inotiv's Interest Coverage Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Inotiv's Interest Coverage falls into.



Inotiv Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Inotiv's Interest Coverage for the fiscal year that ended in Sep. 2023 is calculated as

Here, for the fiscal year that ended in Sep. 2023, Inotiv's Interest Expense was $-43.0 Mil. Its Operating Income was $-9.2 Mil. And its Long-Term Debt & Capital Lease Obligation was $399.4 Mil.

Inotiv did not have earnings to cover the interest expense.

Inotiv's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Inotiv's Interest Expense was $-11.4 Mil. Its Operating Income was $-8.3 Mil. And its Long-Term Debt & Capital Lease Obligation was $409.0 Mil.

Inotiv did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Inotiv  (NAS:NOTV) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Inotiv Interest Coverage Related Terms

Thank you for viewing the detailed overview of Inotiv's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Inotiv (Inotiv) Business Description

Traded in Other Exchanges
Address
2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
Executives
John Gregory Beattie officer: Chief Operating Officer C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Michael Garrett officer: Chief Commercial Officer 250 PEHLE DRIVE, SUITE 601, SADDLE BROOK NJ 07663
Andrea Castetter officer: SVP, Gen. Counsel & Secretary 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Mary Theresa Coelho director 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
John E Sagartz director, officer: Chief Strategy Officer 19 WORTHINGTON ACCESS DRIVE, MARYLAND HEIGHTS MO 63043
David Landman director 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Robert Jr. Leasure director, officer: President and CEO C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Beth Taylor officer: Chief Financial Officer 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Jeffrey Arthur Krupp officer: Chief Human Resources Officer 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
William D Pitchford officer: Chief Human Resources Officer 1000 SAGAMORE PARKWAY SOUTH, LAFAYETTE IN 47905
R Matthew Neff director 535 N. COLLEGE DRIVE, CARMEL IN 46032
Jeffrey Brennan Freeman officer: VP-Finance & Corp. Controller 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Davis Gregory Cole director C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Nigel Brown director 250 PEHLE AVENUE, SUITE 600, SADDLE BROOK NJ 07663
Scott Cragg director 660 MADISON AVENUE, NEW YORK NY 10065